Roell, William C.

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 882

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.

Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 316

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation

Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases

Cited by 256

Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation

Ravussin, E., Sanchez-Delgado, G., Martin, C. K., Beyl, R. A., Greenway, F. L., O’Farrell, L. S., Roell, W. C., Qian, H.-R., Li, J., Nishiyama, H., et al. (2025) · Cell Metabolism

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 72

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy

Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 41

56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting

KNOP, F. K., URVA, S., RETTIGANTI, M., BENSON, C., ROELL, W., MATHER, K. J., HAUPT, A., & PRATT, E. J. (2023) · Diabetes

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 29

679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes

COSKUN, T., MOYERS, J. S., ROELL, W. C., O’FARRELL, L., REGMI, A., RUAN, X., SHOWALTER, A. D., SLOOP, K., WAINSCOTT, D. B., WILLARD, F. S., et al. (2021) · Diabetes

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 10